Safety of levetiracetam as adjunctive therapy in epilepsy: The skate trial in Spain;Seguridad del levetiracetam como tratamiento adyuvante en la epilepsia: El estudio skate en España

Revista de Neurologia

Volumn 38, Issue 12, 2004, Pages 1117-1122

  Salas Puig, Javier ^a   Serratosa, J M ^b   Viteri, C ^c   Gil Nagel Rein ^d   Acosta, J ^e   Alias, E J ^e   Morales, J M ^e   Alvarez J ^e   Arias, M ^e   Arbizu, T ^e   Asensio, M ^e   Bertol, V ^e   Burcet, J ^e   Cabeza, C I ^e   Cebrian E ^e   Codina, M ^e   Comes, E ^e   Corredera, E ^e   Cristobal S ^e   De Juan, P ^e   De La Pena P ^e   Dominguez M ^e   Escartin, A ^e   Escudero, J ^e   Estruch, J ^e   Fernandez J F ^e   Forcadas, M I ^e   Fossas, P ^e   Garcia M ^e   Garcia A ^e   Garcia C ^e   Garcia Monco J C ^e   Gimenez F ^e   Goberna, E ^e   Gomez Alonso J ^e   Gomez Diaz A ^e   Gonzalez A ^e   Granes P ^e   Gudin M ^e   Herraiz J ^e   Iriondo, I ^e   Lopez Facal J T ^e   Lopez M S ^e   Lopez E ^e   Lopez Trigo J ^e   Lorenzo, J R ^e   Lousa, M ^e   Marquez J ^e   Martin J J ^e   Martin Moro M ^e   Martinez J I ^e   Martinez F ^e   Mauri, J A ^e   Molins, A ^e   Morales, M D ^e   Moreno, V ^e   Oliveros, A ^e   Oller, L F V ^e   Ortiz, M R ^e   Oterino, A ^e   Padilla, F ^e   Padro Ll ^e   Pastor, E ^e   Picornell, I ^e   Ribacoba, R ^e   Rodriguez J M ^e   Rubio, G ^e   Russi, A ^e   Sanchez C ^e   Sancho, J ^e   Tejeiro, J ^e   Vidal, J A ^e   Villalobos, F ^e   Villar, M E ^e   Villanueva, J A ^e   Villarroya, M T ^e   Zabala, J A ^e   more..

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HOSPITAL RUBER INTERNACIONAL   (Spain)

^e Hospital Central de Asturias ^*

Author keywords

Antiepileptic drugs; Epilepsy; Keppra; Levetiracetam; Partial seizures; QOLIE 10

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID; BROMAZEPAM; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADJUVANT THERAPY; ADULT; ANTICONVULSANT THERAPY; ARTICLE; BRAIN INJURY; BRAIN TUMOR; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGENITAL MALFORMATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; SEIZURE; SOMNOLENCE; SPAIN;

EID: 3543108346     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3812.2004259     Document Type: Article

References (18)

1. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996; 61: 433-43.
2. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43.
3. Hauser WA, Hesdorffer DC. Incidence and prevalence. In Hauser WA, Hesdorffer DC, eds. Epilepsy: frequency, causes and consequences. New York: Demos; 1990. p. 1-51.
4. Keranen T, Sillanpaa M, Riekkinen PJ. Distribution of seizure types in an epileptic population. Epilepsia 1988; 29: 1-7.
5. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
6. Lesser RP, Pippenger CE, Lüders H, Dinner DS. High-dose monotherapy in treatment of intractable seizures. Neurology 1984; 34: 707-11.
7. Schmidt D, Richter K. Alternative single anticonvulsant drug therapy for refractory epilepsy. Ann Neurol 1986; 19: 85-7.
8. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2: 99-105.
9. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-86.
10. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
11. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-83.
12. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-7.
13. Olwen GO. The SKATE study: interim analysis. Int J Clin Pract 2003; 57: 544-5.
14. Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 1996; 37: 577-82.
15. Cramer JA, Arrigo C, Van Hammee G, Bromfield EB. Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. Epilepsy Res 2000; 41: 29-38.
16. Commission on classification and terminology of the International League against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501.
17. Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day (-1) in adult patients with refractory epilepsy. Seizure 2003; 12: 141-9.
18. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEE-PER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003; 54: 153-61.